Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective

OBJECTIVE: Malignancy in giant cell tumor of bone (mGCTB) is categorized as primary (concomitantly with conventional GCTB) or secondary (after radiotherapy or other treatment). Denosumab therapy has been suggested to play a role in the etiology of secondary mGCTB. In this case series from a tertiary...

Descripción completa

Detalles Bibliográficos
Autores principales: van Langevelde, K., Cleven, A. H. G., Navas Cañete, A., van der Heijden, L., van de Sande, M. A. J., Gelderblom, H., Bovée, J. V. M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262566/
https://www.ncbi.nlm.nih.gov/pubmed/35814640
http://dx.doi.org/10.1155/2022/3425221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262566/
https://www.ncbi.nlm.nih.gov/pubmed/35814640
http://dx.doi.org/10.1155/2022/3425221

Ejemplares similares